50 results about "Urethral infection" patented technology

The invention discloses a medicine-carrying nano antibacterial super-smooth coating for marine organisms. The medicine-carrying nano antibacterial super-smooth coating comprises a medicine-carrying nano antibacterial slow-release coating and a hydrophilic coating, wherein the medicine-carrying nano antibacterial slow-release coating comprises medicine-carrying nano particles and antibacterial substances; the medicine-carrying nano particles have effects of restraining and preventing bacteria and sustaining release, and have bacteria-inhibiting effects on escherichia coli, staphylococcus aureus, candida albicans and the like which cause urinary tract infection easily; the antibacterial substances further can improve the antibacterial effects of the medicine-carrying nano antibacterial slow-release coating, so that the medicine-carrying nano antibacterial slow-release coating achieves lasting and stable antibacterial effects; after contacting water, substances of the hydrophilic layer can quickly form a lubricating film, so that the conduit surface is sufficiently and efficiently lubricated, and the conduit is conveniently and quickly implanted; after the conduit is implanted, the hydrophilic polymer is dissolved into water to play synergetic bacteriostatic action with the medicine-carrying nano particles and the antibacterial substances, and the loaded bacteria-restraining components are slowly released to finally achieve the lasting and stable antibacterial effects.

The invention discloses a compound bergamot oil nano-emulsion composition, which is characterized in that: the granularity of the nano-emulsion is 1nm to 100nm, and comprises the following substances by weight mass: 23 to 35 percent of surface active agent, 0.3 to 8 percent of cosurfacant, 1.5 to 10 percent of bergamot oil, 0.5 to 5.5 percent of patchouli, 0.4 to 4.5 percent of tea tree oil, 0.3 to 2.2 percent of pennyroyal and distilled water, wherein the sum of the mass percentage of the ingredients is 100 percent. The compound bergamot oil nano-emulsion composition is broad-spectrum antimicrobic, has good treatment effect on eczema, psoriasis, herpes, dermatitis, blain, wound, acne, urinary infection and the like, the permeability is strong, the stability is good, content of active ingredients is high, transdermal absorption effect is remarkable, action time is durable, the preparation method is simple and is easy to popularize and use, and the medicine has vast application prospect on the medical market.

The invention discloses a new medicine for curing urethral infection and the preparing method thereof, prepared of raw materials such as Membranous Milkvetch Root, Pink Herb, Fuling, Common Yan Rhizome, Prepared Common Monkshood Daughter Root, and Rhizoma Smilacis Glabrae processed by different physical or chemical methods according to their different physical or chemical properties into acceptable forms in clinical practice. Its formula is peculiar, and it is used for curing urethral infection in clinical practice, having remarkable curative effect.

A Chinese medicine in the form of particles for treating urethral infection is prepared from common sage herb, plantain herb, threeflower bluebeard, and to kyo violet herb.

The invention discloses a novel method for screening anti-bacterial adhesion inhibitors and preparation of anti-bacterial adhesion oral liquid. The novel method disclosed by the invention comprises the following steps of: immersing a glass slide with a specific shape into a liquid culture medium to carry out bacterial adhesion; adding a screened sample into the culture medium; and analyzing and judging anti-bacterial adhesion medicinal effect through a microscopic image. The anti-bacterial adhesion oral liquid disclosed by the invention is prepared from the raw materials including pilea notata, honeysuckle and poria cocos through extracting, liquid matching, fermenting, freezing and centrifugal processes and has the pharmaceutical effects of resisting bacterial adhesion, intestinal infection, urinary tract infection and cold.

The invention discloses a urogenital tract infection pathogen multiple detection kit and application thereof. Specifically, the invention develops a fluorescent quantitative PCR (Polymerase Chain Reaction) kit for detecting 12 clinical common urethral infection germs. The optimized primer and probe provided by the invention have more excellent combination of 12 groups of PCR primers and probes, have excellent stability, and do not interfere with each other in a PCR reaction process, so that the optimized primer and probe can be used for a multiplex fluorescent quantitative PCR method.

A method for detecting inflammation in the urinary tract or urethra of a patient, especially urethritis, comprises a) contacting leucocytes obtained from a urine sample provided by the patient with a luminescence reagent which emits light on reaction with an oxidant; b) adding an activator to the mixture of leucocytes and luminescence reagent; c) continuously monitoring and/or measuring light emitted by the luminescence reagent over a predetermined time period commencing before and ending after the addition of the activator. The light emission is indicative of the presence or absence of inflammation in the urinary tract or urethra of the patient. The urine sample is preferably a sample of first pass urine. The method makes possible a diagnosis especially of urethritis and, in particular, urethral infections selected from Chlamydia trachomatis and Neisseria gonorrhoeae, which can be carried out quickly without invasive procedures. A diagnostic kit for carrying out the method, comprising a luminescence reagent which emits light on reaction with an oxidant, an activator and a library of standard signature light emission curves is also disclosed.

Catheter-adapted briefs operative to stabilize an indwelling urethra catheter in a position of alignment with the natural orientation of the male urethral orifice to minimize catheter discomfort, prevent urine leakage, tissue damage, and reduce the frequency of urinary track infection.

The invention discloses a preparation method of magnesium boride nanoparticles. According to liquid phase plasma technology, the magnesium boride nanoparticles are synthesized by reducing MgCl2 with borane in triethylphenylammonium bis (trifluoromethanesulfonyl) imine ionic liquid at room temperature. Compared with commercial magnesium boride, the prepared magnesium boride nanoparticles are largerin specific surface area and stronger in antibacterial effect. Compared with amikacin and vertilmicin sulfate, the magnesium boride nanoparticles prepared by the invention show stronger antibacterialactivity on enterobacter cloacae. Through the excellent antibacterial property of the enterobacter cloacae, the wide application of magnesium boride in the clinical treatment fields of hospital infected bacterial infectious diseases, such as skin soft tissue infection, urinary tract infection, respiratory tract infection and septicemia is expected to expand.

The invention provides a prescription for treating urinary tract infection. The prescription comprises, by weight, 60g of polygonum aviculare, 30g of plantago asiatica, 15g of lonicera japonica and 3g of radix glycyrrhizae. The prescription for treating the urinary tract infection has the advantages that the prescription is applicable to patients with the urinary tract infection caused by various causes, and the prescription is capable of increasing the acidity of urine to allow various bacteria inducing the urinary tract infection to be not able to survive, comprehensively and effectively killing pathogenic bacteria, eliminating in-vivo viruses and thoroughly curing the urinary tract infection and free of side effects.

The invention relates to medical appliances and particularly relates to a multifunctional dual-sacculus urethral catheter. The multifunctional dual-sacculus urethral catheter comprises a catheter part, a sacculus part and a topping-up part. The multifunctional dual-sacculus urethral catheter mainly comprises a urethral catheter main pipe, a urine inlet, a bladder sacculus, a urinary tract sacculus, a urinary tract sacculus drain hole, a bladder sacculus topping-up one-way valve, a urinary tract sacculus topping-up one-way valve and a urine discharge opening. The urinary tract sacculus drain hole is formed in the edge of the end part of the urinary tract sacculus. According to the multifunctional dual-sacculus urethral catheter, besides having functions of an ordinary urethral catheter, through injecting normal saline or other medicated liquid into the urinary tract sacculus, a urinary tract can be cleaned and lubricated, or a drug can be continuously supplied into the urinary tract fora long time to prevent and treat urinary-tract infection, and the risk of serious complications such as urinary-tract infection of patients with long-term urethral catheter reserving is lowered. Themultifunctional dual-sacculus urethral catheter can also be applied to dilation treatment on urethral stricture and direct-administration treatment on prostate disorders. The multifunctional dual-sacculus urethral catheter is simple in structure, low in cost, safe and convenient in use and convenient in large-batch production. The multifunctional dual-sacculus urethral catheter is applicable to all patients needing to reserve a urethral catheter for 24 hours or more.

A Chinese medicine ''Niaoganning'' is prepared from 5 Chinese-medicinal materials including lygodium spores stem, longtube groundivy herb, Chinese brake herb, Tokyo violet herb, etc. Its preparing process is also disclosed.

Prevention of recurrence of urethral stricture after a conventional treatment. Composition applicable to the prevention of recurrence of urethral stricture after a conventional treatment, including a pharmaceutically effective amount of halofuginone. Urethral stricture, a common disease, appears secondary to urethritis, urethral infection, urethral inflammation, urethral instrumentation, urethral catheterization, urethral trauma, urethral surgery and all types of urethral lesions. Conventional treatments by internal urethrotomy, urethral dilation or surgical urethroplasty are available and can cure urethral stricture, but with a relatively high rate of recurrence of the stricture. Halofuginone can prevent the recurrence of urethral stricture after a conventional treatment via internal urethrotomy, urethral dilation or surgical urethroplasty.

The invention relates to a catheterization device and a catheterization external member. The catheterization device comprises a first structure part placed in a bladder of a patient and a second structure part kept in the urethra of the patient, wherein a catheterization cavity in the first structure part communicates with a catheterization passage in the second structure part; the second structure part is elastically opened in the urethra of the patient, and is fixed in the urethra; the first structure part is also provided with a plurality of catheterization openings communicating with the catheterization cavity, an on-off mechanism is arranged at each catheterization opening, the on-off mechanisms are opened when the external pressure of the first structure part reaches set pressure andenable the catheterization cavity to communicate with the bladder of the patient, and the on-off mechanisms are closed when the external pressure of the first structure part is smaller than the set pressure and enable the catheterization cavity not to communicate with the bladder of the patient. The catheterization device disclosed by the invention is simple and compact in structure, is convenient to mount, use and disassemble, can be kept in the body of the patient for a long term, can greatly reduce the infection rick of the urethra and can also effectively reduce the cost.